Anti-CD27 [RM27-3E5]

Absolute Antibody

Anti-CD27 [RM27-3E5]

9

This antibody is specific for the extracellular domain of murine CD27, a TNF-receptor superfamily member.

This antibody recognises murine CD27, as confirmed by flow-cytometry and immunoprecipitation analysis (Sakanishi & Yagita, 2010), a member of the TNF-receptor superfamily. The interaction between CD27 and its ligand CD70, which is recognised by anti-CD70 antibody TAN 1-7 (Ab00816), is crucial to regulation of the survival and differentiation of T cells, B cells and NK cells. As a result, RM27-3E5 modulates multiple immune cell types. The original rat IgG2a version of RM27-3E5 did not deplete T cells, NKT or NK cells, but does enhance the proliferation of anti-CD3-stimulated splenic T cells (Sakanishi & Yagita, 2010). In murine models of melanoma, it promotes the persistence of tumour-specific CD8+ T cells within tumours, and reduces levels of PD-1 expression on CD8+ T cells (Roberts et al, 2010). Additionally, anti-CD27 reduces the proportion of FoxP3+ CD4+ T cells in tumours, and enhances the effector activity of IFNgamma-secreting, tumour-infiltrating CD8+ T cells and NK cells (Roberts et al, 2010). Finally, anti-CD27 Ab treatment alters murine splenocyte cytokine production, significantly reducing IL-5 and IFN-gamma synthesis, and increasing TNF-alpha production (Sumi et al, 2008). It also significantly suppresses total serum IgE levels, while significantly increasing IgG1 and IgG2a levels. These immune modulatory properties translate into potent anti-tumour effects in mice. Treatment of established murine melanoma with RM27-3E5 (rat IgG2a) resulted in a significant reduction in lung metastases and subcutaneous tumours, through an IFNgamma-dependent mechanism mediated by CD8+ T cells and NK cells (Roberts et al, 2010). In murine models of T cell lymphoma, the tumour-specific CTL response induced by RM27-3E5 (rat IgG2a) promoted almost complete regression of tumours, regardless of CD27 expression on tumour cells (Sakanishi & Yagita, 2010). This antibody has been used to identify CD27-expressing cells through flow-cytometry (Koyanagi et al, 2012).

Flow Cytometry, ImmunoPrecipitation, Neutralisation/Blocking

Research Use Only

Monoclonal

RM27-3E5

Cd27

CD27 antigen

CD antigen 27; CD27 antigen; CD27L receptor; S15; S152; T-cell activation antigen CD27; Tnfr; Tnfrsf7; Tp5; Tp55; tumor necrosis factor receptor superfamily member 7

Human

IgG1

CD27 antigen

This chimeric human antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques.

Mouse

-20°C,2°C to 8°C

12352203